Human IL6 Enhances Leptin Action in Mice

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2009 Nov 11

PMID 19902173

Citations 59

Authors

M Sadagurski

L Norquay

J Farhang

K DAquino

K Copps

M F White

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: Interleukin-6 is an inflammatory cytokine with pleiotropic effects upon nutrient homeostasis. Many reports show that circulating IL6 correlates with obesity and contributes to insulin resistance; however, IL6 can promote energy expenditure that improves glucose homeostasis.

Methods: We investigated nutrient homeostasis in C57BL/6J mice with sustained circulating human IL6 (hIL6) secreted predominantly from brain and lung (hIL6(tg) mice).

Results: The hIL6(tg) mice displayed no features of systemic inflammation and were more insulin-sensitive than wild-type mice. On a high-fat diet, hIL6(tg) mice were lean, had low leptin concentrations, consumed less food and expended more energy than wild-type mice. Like ob/ob mice, the ob/ob (IL6) mice (generated by intercrossing ob/ob and hIL6(tg) mice) were obese and glucose-intolerant. However, low-dose leptin injections increased physical activity and reduced both body weight and food intake in ob/ob (IL6) mice, but was ineffective in ob/ob mice. Leptin increased hypothalamic signal transducer and activator of transcription-3 phosphorylation in ob/ob (IL6) mice, whereas ob/ob mice barely responded.

Conclusions/interpretation: Human IL6 enhanced central leptin action in mice, promoting nutrient homeostasis and preventing diet-induced obesity.

Citing Articles

IL-6 and diabetic kidney disease.

Zhang L, Xu F, Hou L Front Immunol. 2025; 15:1465625.

PMID: 39749325 PMC: 11693507. DOI: 10.3389/fimmu.2024.1465625.

Circulating chemerin and interleukin-6 in children with obesity: possible metabolic risk predictors.

Zhang J, Gu C, Deng M, Yang L, Yang W Transl Pediatr. 2024; 13(10):1760-1766.

PMID: 39524379 PMC: 11543120. DOI: 10.21037/tp-24-264.

CLCF1 signaling restrains thermogenesis and disrupts metabolic homeostasis by inhibiting mitochondrial biogenesis in brown adipocytes.

Ding M, Xu H, Zhou W, Xia Y, Li B, Shi Y Proc Natl Acad Sci U S A. 2023; 120(33):e2305717120.

PMID: 37549287 PMC: 10433725. DOI: 10.1073/pnas.2305717120.

Interleukin-6 Drives Mitochondrial Dysregulation and Accelerates Physical Decline: Insights From an Inducible Humanized IL-6 Knock-In Mouse Model.

Nidadavolu L, Cosarderelioglu C, Merino Gomez A, Wu Y, Bopp T, Zhang C J Gerontol A Biol Sci Med Sci. 2023; 78(10):1740-1752.

PMID: 37310873 PMC: 10562892. DOI: 10.1093/gerona/glad147.

Prenatal benzene exposure in mice alters offspring hypothalamic development predisposing to metabolic disease in later life.

Koshko L, Scofield S, Debarba L, Stilgenbauer L, Fakhoury P, Jayarathne H Chemosphere. 2023; 330:138738.

PMID: 37084897 PMC: 10199724. DOI: 10.1016/j.chemosphere.2023.138738.

References

Pedersen B, Bruunsgaard H, Ostrowski K, Krabbe K, Hansen H, Krzywkowski K . Cytokines in aging and exercise. Int J Sports Med. 2000; 21 Suppl 1:S4-9. DOI: 10.1055/s-2000-1444. View

Inoue H, Ogawa W, Asakawa A, Okamoto Y, Nishizawa A, Matsumoto M . Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 2006; 3(4):267-75. DOI: 10.1016/j.cmet.2006.02.009. View

Dong X, Park S, Lin X, Copps K, Yi X, White M . Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J Clin Invest. 2005; 116(1):101-14. PMC: 1319221. DOI: 10.1172/JCI25735. View

Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S . IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A. 1989; 86(19):7547-51. PMC: 298102. DOI: 10.1073/pnas.86.19.7547. View

Buettner C, Pocai A, Muse E, Etgen A, Myers Jr M, Rossetti L . Critical role of STAT3 in leptin's metabolic actions. Cell Metab. 2006; 4(1):49-60. PMC: 3638026. DOI: 10.1016/j.cmet.2006.04.014. View

Schuster B, Kovaleva M, Sun Y, Regenhard P, Matthews V, Grotzinger J . Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF. J Biol Chem. 2003; 278(11):9528-35. DOI: 10.1074/jbc.m210044200. View

Lieskovska J, Guo D, Derman E . IL-6-overexpression brings about growth impairment potentially through a GH receptor defect. Growth Horm IGF Res. 2002; 12(6):388-98. DOI: 10.1016/s1096-6374(02)00079-5. View

Ernst M, Jenkins B . Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 2003; 20(1):23-32. DOI: 10.1016/j.tig.2003.11.003. View

Pedersen B . IL-6 signalling in exercise and disease. Biochem Soc Trans. 2007; 35(Pt 5):1295-7. DOI: 10.1042/BST0351295. View

10.

Katsume A, Miyai T, Suzuki H, Moriguchi Y, Kawata H, Tatsumi T . Interleukin-6 overexpression cannot generate serious disorders in severe combined immunodeficiency mice. Clin Immunol Immunopathol. 1997; 82(2):117-24. DOI: 10.1006/clin.1996.4278. View

11.

Vozarova B, Weyer C, Hanson K, Tataranni P, Bogardus C, Pratley R . Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001; 9(7):414-7. DOI: 10.1038/oby.2001.54. View

12.

Febbraio M, Hiscock N, Sacchetti M, Fischer C, Pedersen B . Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes. 2004; 53(7):1643-8. DOI: 10.2337/diabetes.53.7.1643. View

13.

Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

14.

Klover P, Zimmers T, Koniaris L, Mooney R . Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003; 52(11):2784-9. DOI: 10.2337/diabetes.52.11.2784. View

15.

Spiegelman B, Flier J . Obesity and the regulation of energy balance. Cell. 2001; 104(4):531-43. DOI: 10.1016/s0092-8674(01)00240-9. View

16.

Lebrun P, Van Obberghen E . SOCS proteins causing trouble in insulin action. Acta Physiol (Oxf). 2008; 192(1):29-36. DOI: 10.1111/j.1748-1716.2007.01782.x. View

17.

Klover P, Clementi A, Mooney R . Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology. 2005; 146(8):3417-27. DOI: 10.1210/en.2004-1468. View

18.

Steinberg G, Watt M, Fam B, Proietto J, Andrikopoulos S, Allen A . Ciliary neurotrophic factor suppresses hypothalamic AMP-kinase signaling in leptin-resistant obese mice. Endocrinology. 2006; 147(8):3906-14. DOI: 10.1210/en.2005-1587. View

19.

Raber J, OShea R, Bloom F, Campbell I . Modulation of hypothalamic-pituitary-adrenal function by transgenic expression of interleukin-6 in the CNS of mice. J Neurosci. 1998; 17(24):9473-80. PMC: 6573407. View

20.

Ruderman N, Keller C, Richard A, Saha A, Luo Z, Xiang X . Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes. 2006; 55 Suppl 2:S48-54. DOI: 10.2337/db06-s007. View